A prospective, observational study of effectiveness and safety of ABP 501 in Crohn's Disease patients naive to adalimumab and the biosimilar adalimumab maintenance in Crohn's Disease patients who switched from the adalimumab originator
Latest Information Update: 21 Jul 2021
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
Most Recent Events
- 21 Jul 2021 New trial record